NovaQuest Capital Management, a private equity firm focused on life sciences, provides direct investment into pharmaceutical R&D and commercialization of products. They needed a fast turnaround asset evaluation of Pfizer’s Rivipansel, an experimental Phase 3 drug to treat Vaso-Occlusive Crisis in Sickle Cell Disease. Read this case study to learn how Certara developed a strategic and programmatic approach that identified potential R&D, regulatory, or commercial show-stoppers, created a costed and stage-gated development plan, and leveraged clinical pharmacology technologies that will increase the speed and efficiency of developing this new medication.
